Table 1.
Demographic characteristics, lung function tests, sestrin2 results of the asthma and control groups
| Control group (n = 32) | Asthma group (n = 44) | p value | |
|---|---|---|---|
| Age (years) | 41.66 ± 7.74 | 42.95 ± 8.47 | 0.496 |
| Gender, male (n, %)a | 15 (46.88) | 21 (47.73) | 0.563 |
| BMI (kg/m2) | 26.45 ± 3.06 | 27.26 ± 3.98 | 0.338 |
| Smoking index (pack year) | 3.22 ± 7.91 | 2.52 ± 6.06 | 0.665 |
| Treatment before enrollment | |||
| ICS (never/former or current) | – | 19/25 | – |
| LABA (never/former or current) | – | 28/16 | – |
| SABA (never/former or current) | – | 7/37 | – |
| LAMA (never/former or current) | – | 21/13 | – |
| Causes of exacerbation | |||
| Allergen exposure | – | 9 | – |
| Poor adherence | – | 18 | – |
| Respiratory infection | – | 13 | – |
| Undistinguishable | – | 4 | – |
| PEF (l/min) | 318.8 ± 47.91 | 243.75 ± 43.18 | < 0.001* |
| 311.75 ± 36.11# | |||
| FEV1% predicted (%) | |||
| Before treatment | 91.57 ± 13.68 | 67.90 ± 15.66 | < 0.001* |
| After treatment | – | 72.35 ± 11.78# | – |
| FVC% predicted (%) | |||
| Before treatment | 95.75 ± 11.06 | 82.94 ± 12.54 | < 0.001* |
| After treatment | – | 90.30 ± 10.84# | – |
| FEV1/FVC ratio (%) | |||
| Before treatment | 88.80 ± 5.29 | 77.35 ± 14.54 | < 0.001* |
| After treatment | – | 82.98 ± 2.11# | – |
| Sestrin2 (ng/mL) | |||
| Before treatment | 1.32 ± 0.48 | 1.75 ± 0.53 | < 0.001* |
| After treatment | – | 1.56 ± 0.46# | – |
| Treatment time in hospital (days) | – | 3.64 ± 1.95 | – |
Data are presented as mean ± SD
BMI body mass index, PEF peak expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting beta2-agonist, SABA short-acting beta2-agonist, LAMA long-acting muscarinic antagonist
* Statistically significant difference
# P < 0.05, vs. before treatment
aData are presented as number and rate